Professional Documents
Culture Documents
CHLA
September 21, 2006
Akshay Lal
Vice President, Strategic Licensing & Sourcing
Pharmascience Inc.
Presentation Structure
India Advantage
Phase V
Phase IV
Innovation and Research
Growth Phase •New IP law
Phase III
Development Phase •Rapid expansion of •Discovery Research
domestic market
•Process •Convergence
Phase II development •International market
Government Control development
•Production
Phase I •Indian Patent Act – infrastructure •Research orientation
Early Years 1970 creation
•Market share •Drug prices capped •Export initiatives
domination by •Local companies begin
foreign companies to make an impact
•Relative absence
of organized
Indian companies
Innovative
Products
Specialty
Generic
Generic exports Products
exports to
to under- developed
developed & countries
developing
API
countries
Exports
TIME
India Advantage
Speed
Very strong entrepreneurial spirit
Hungry for growth and recognition
Quick learners and fast movers
Availability of capital
Stock market has seen unprecedented growth in the last decade
Continues to be bullish on the pharma industry
Emerging Trends & Opportunities
Geographic Convergence
Established and growing destination for Generic product
development and manufacturing
Leading Indian companies seeking overseas markets and
global scale
No place like India for generics R&D and manufacturing of API’s &
formulations
India’s biggest assets – cost, speed & scientists – churning out generics
faster than you can say ‘copy’
In 5 years, 30-35% of the global demand for generic products is expected to
be met by India
Generic Product Development &
Manufacturing Destination – cont.
Partnership opportunities
Large number of large and mid-sized Indian companies with world-class
generic product development and manufacturing capabilities and facilities
Lot of under-utilized manufacturing capacities
These companies prefer focusing attention & resources on some key markets
(US/EU) and look for partners in other markets
Opportunities for supplementing pipelines, filling pipeline gaps and
reducing/optimizing cost of development and cost of goods:
In-licensing products
Contract Manufacturing
Some examples:
Ranbaxy
1 project in Phase II
1 project in Phase I
7 projects in Pre-Clinical – 2 with GSK
Dr. Reddy’s
3 projects in Phase II
2 projects in Phase I
4 projects in Pre-Clinical
Glenmark
2 projects in Phase II – deals with US$ 190 million signed
4 projects in Pre-Clinical
Merci!